Project information
Alternative mechanisms of deregulation of the p53 pathway in chronic lymphocytic leukemia
- Project Identification
- GA19-15737S (kod CEP: GA19-15737S)
- Project Period
- 1/2019 - 6/2022
- Investor / Pogramme / Project type
-
Czech Science Foundation
- Standard Projects
- MU Faculty or unit
-
Central European Institute of Technology
- prof. RNDr. Šárka Pospíšilová, Ph.D.
- Mgr. Veronika Mančíková, Ph.D.
- Cooperating Organization
-
University Hospital Brno-Bohunice
Eventually almost all cancers escape the tumor suppression control by the key genome guardian p53, most frequently by genetic mutations but also by other mechanisms. Defects in p53 are widely accepted to be the most significant marker of poor prognosis among chronic lymphocytic leukemia (CLL) patients. We hypothesize that apart from a direct genetic impairment, other mechanisms acting upon p53 protein could be driving CLL. Therefore, we plan to portray the landscape of phosphorylation modifications of p53 in primary human CLL cells treated with a clinically relevant drug set. We anticipate to identify differences among patients with distinct genetic background and with diverse clinical outcome.
Publications
Total number of publications: 15
2021
-
The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer
Frontiers in Oncology, year: 2021, volume: 10, edition: JAN, DOI
2020
-
Dynamika vývoje mutací TP53 u pacientů s chronickou lymfocytární leukemií během léčby BCR inhibitory.
Year: 2020, type: Conference abstract
-
LYNX (Lymphoid NGS): a versatile NGS panel for comprehensive analysis of molecular markers with clinical relevance in lymphoproliferative disorders
Year: 2020, type: Conference abstract
-
Minor-clone TP53 mutations in CLL patients entering first-line treatment: clonal evolution and clinical impact.
Year: 2020, type: Conference abstract
2019
-
Dynamika vývoje mutací TP53 u pacientů s chronickou lymfocytární keukémií během léčby BCR inhibitory.
Year: 2019, type: Conference abstract